UK-based cancer vaccine biotechnology company Infinitopes recently announced the successful completion of its second seed funding round, raising an additional $15.4 million, bringing the company's total funding raised to $35.1 million. This financing provides crucial capital support for Infinitopes to advance its innovative therapy research.

Currently, Infinitopes has initiated its first-in-human, double-blind, randomized, placebo-controlled clinical trial—ITOP1. This trial focuses on its leading precision treatment vaccine, aiming to prevent the recurrence of esophageal cancer. As one of the high-incidence malignant tumors, treatment options for esophageal cancer after recurrence are limited, and the clinical need has long been unmet. The ITOP1 vaccine, by activating patient-specific immune responses, holds the potential to fill this treatment gap and provide patients with a new preventive approach.

The head of Infinitopes stated: "This funding will accelerate the clinical development process of the ITOP1 vaccine, driving it to benefit more patients as soon as possible."